Compare WABC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WABC | MPLT |
|---|---|---|
| Founded | 1972 | 2018 |
| Country | United States | United States |
| Employees | 627 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1994 | 2025 |
| Metric | WABC | MPLT |
|---|---|---|
| Price | $59.09 | $13.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $54.00 | $32.67 |
| AVG Volume (30 Days) | 101.5K | ★ 571.1K |
| Earning Date | 04-16-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ 3.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.93 | $9.10 |
| 52 Week High | $63.61 | $40.43 |
| Indicator | WABC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 44.43 |
| Support Level | $58.27 | $10.67 |
| Resistance Level | $60.63 | $20.20 |
| Average True Range (ATR) | 1.04 | 0.95 |
| MACD | 0.04 | 0.80 |
| Stochastic Oscillator | 75.28 | 89.76 |
Westamerica Bancorp provides a full range of banking services to individual and commercial customers in Northern and Central California through its subsidiary bank. The Bank is a California-chartered commercial bank whose deposits are insured by the Federal Deposit Insurance Corporation (the FDIC) up to applicable limits. The principal communities served are located in Northern and Central California, from Mendocino, Lake and Nevada Counties in the north to Kern County in the south. The Company's strategic focus is on the banking needs of small businesses.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.